| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/01/2004 | WO2004055051A1 Transcription control factor zhx3 |
| 07/01/2004 | WO2004055047A1 A novel phosphoprotein |
| 07/01/2004 | WO2004055039A1 Steroid compounds with anti-tumor activity |
| 07/01/2004 | WO2004055022A1 Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases |
| 07/01/2004 | WO2004054999A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors |
| 07/01/2004 | WO2004054995A1 New alpha-glucosidase inhibitors and their synthesis from a natural source |
| 07/01/2004 | WO2004054993A1 A new antioxidant from natural source |
| 07/01/2004 | WO2004054977A1 Nicotinamide-based kinase inhibitors |
| 07/01/2004 | WO2004054968A2 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
| 07/01/2004 | WO2004054657A1 Combined antisense oligonucleotide cancer therapy |
| 07/01/2004 | WO2004054622A1 Immunoconjugates with an intracellularly-cleavable linkage |
| 07/01/2004 | WO2004054620A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054613A1 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| 07/01/2004 | WO2004054585A1 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
| 07/01/2004 | WO2004054577A1 Alpha-2-delta ligands to treat ocd and related diseases |
| 07/01/2004 | WO2004054569A1 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
| 07/01/2004 | WO2004054563A1 Alpha-2-delta ligand for the treatment of sexual dysfunction |
| 07/01/2004 | WO2004054559A1 Alpha2delta ligands for different pharmaceutical uses |
| 07/01/2004 | WO2004054516A2 Antagonists for human prolactin |
| 07/01/2004 | WO2004054507A2 Indolizine compounds |
| 07/01/2004 | WO2004054498A2 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| 07/01/2004 | WO2004054497A2 Use of a trpm8-activating substance for the treatment of tumours |
| 07/01/2004 | WO2004054356A2 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 07/01/2004 | WO2004041859A3 Peptide fragments of the harp factor inhibiting angiogenesis |
| 07/01/2004 | WO2004041834A3 Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| 07/01/2004 | WO2004028541A3 Composition for the treatment of nasopharyngeal carcinoma and use thereof |
| 07/01/2004 | WO2004026306A3 Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| 07/01/2004 | WO2004019865A3 Amelioration of effects of cigarette smoke |
| 07/01/2004 | WO2004018058A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004016612A3 New purine derivatives |
| 07/01/2004 | WO2004013093A3 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004005351A3 Neoplasm specific antibodies and uses thereof |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2004001007A3 Buffered formulations for concentrating antibodies and methods of use thereof |
| 07/01/2004 | WO2003100435A3 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2) |
| 07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003080569A3 Egfr ligands and methods of use |
| 07/01/2004 | WO2003057822A9 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/01/2004 | WO2003045369A9 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses |
| 07/01/2004 | WO2003040366A3 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 07/01/2004 | WO2003012045A3 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 07/01/2004 | WO2002099083A3 Gfats as modifiers of the p53 pathway and methods of use |
| 07/01/2004 | US20040127735 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral |
| 07/01/2004 | US20040127709 Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof |
| 07/01/2004 | US20040127696 Growth differentiation factor-7 |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127562 Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| 07/01/2004 | US20040127561 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings, method therefor |
| 07/01/2004 | US20040127555 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127539 Antiangiogenic combination therapy for the treatment of cancer |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127508 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 07/01/2004 | US20040127498 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 07/01/2004 | US20040127496 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127478 Inhibitors of matrix metalloproteinases |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127464 potent, selective and safe inhibitors of the Ca2+-activated potassium channel |
| 07/01/2004 | US20040127452 C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them |
| 07/01/2004 | US20040127441 Compositions and Methods for Treatment of Prostate and Other Cancers |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127437 Combined therapeutical treatment of hyperproliferative diseases |
| 07/01/2004 | US20040127435 Uses for inhibitors of inosine monophosphate dehydrogenase |
| 07/01/2004 | US20040127429 glycolipid ligand for natural killer T (NKT) cells; synthetic analogs of alpha -C-galactosylceramides |
| 07/01/2004 | US20040127407 capable of interfering with the prolactin signaling mechanism in a cancer cell; inhibits STAT-5 phosphorylation in a targeted cell; angiogenesis inhibiting domain can be endostatin, angiostatin or FLK-1-bp |
| 07/01/2004 | US20040127405 Methods for treating lung infections and lung tumors and for treating and preventing lung metastases |
| 07/01/2004 | US20040127401 CA125 gene and its use for diagnostic and therapeutic interventions |
| 07/01/2004 | US20040126870 Ncc2705-the genome of a bifodobacterium |
| 07/01/2004 | US20040126869 Method of producing infectious reovirus |
| 07/01/2004 | US20040126862 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 07/01/2004 | US20040126858 Comprises enzymatic polypeptide for use in identification of modulators for prevention and treatment of free radical damage, inflammatory, metabolic and cancer disorders |
| 07/01/2004 | US20040126825 Using a compounds ability to decrease integrin activation as a diagnostic tool for the identification of antagonistic modulators of neovascularizaton; antitumor/antiproliferative agents |
| 07/01/2004 | US20040126801 Novel polynucleotides and encoded polypeptides |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126791 Compositions and methods for treating trail-resistant cancer cells |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126434 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| 07/01/2004 | US20040126420 phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and cholesterol; for removal of extra-/intra- vascular fibrin clots/adhesions; for use during surgery; for treatment of otitis |
| 07/01/2004 | US20040126394 Novel composition |
| 07/01/2004 | US20040126392 Using plant extract |
| 07/01/2004 | US20040126363 Cd19-specific redirected immune cells |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | DE10261825A1 Verwendung von Hypericin und/oder dessen Derivaten zur Tumorprävention Use of hypericin and / or its derivatives for the prevention of tumor |
| 07/01/2004 | CA2510323A1 4-anilino quinazoline derivatives for the treatment of abnormal cell growth |
| 07/01/2004 | CA2510227A1 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| 07/01/2004 | CA2509825A1 Antagonists for human prolactin |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 07/01/2004 | CA2509283A1 Steroid compounds with anti-tumor activity |
| 07/01/2004 | CA2509214A1 Indolizine compounds |
| 07/01/2004 | CA2507629A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors |
| 06/30/2004 | EP1433855A2 Plasmids suitable for il-2 expression |
| 06/30/2004 | EP1433789A1 Pyrrolopyrazines and their use as selective apoptosis inducers |